Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 9/20 | 0.46 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4689099 | 0.86 | HSD11B1 (0.42) | HSD11B1FFAR4LMNAHTTMEN1 | |
| SCHEMBL964509 | 0.86 | MAPK1 (0.43) | FFAR4 | |
| SCHEMBL13067453 | 0.85 | L3MBTL1 (0.44) | HSD11B1FFAR4KMT2A | |
| SCHEMBL13067135 | 0.85 | HSD11B1 (0.34) | HSD11B1FFAR4 | |
| SCHEMBL2083953 | 0.83 | CA12 (0.39) | LMNAHTTMEN1KMT2A | |
| SCHEMBL31377741 | 0.81 | HSD11B1 (0.53) | HSD11B1MEN1KMT2A | |
| SCHEMBL4398729 | 0.80 | MGLL (0.36) | HSD11B1FFAR4LMNA | |
| SCHEMBL2085855 | 0.80 | HSD11B1 (0.34) | HSD11B1LMNAMEN1KMT2A | |
| SCHEMBL4053345 | 0.78 | EGFR (0.32) | LMNAMEN1KMT2A | |
| SCHEMBL13242104 | 0.78 | SLC6A4 (0.36) | LMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178665-B2 | Process for the production of ezetimibe and intermediates used in this process | RICHTER GEDEON NYRT. (HU) | 2012-05-15 | — | — | US | claimed |
| EP-1963260-B1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT (HU) | 2010-11-03 | — | — | EP | claimed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | claimed |
| EP-1963260-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | Richter Gedeon NYRT (HU) | 2008-09-03 | — | — | EP | claimed |
| WO-2007072088-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | claimed |
| US-8178665-B2 | Process for the production of ezetimibe and intermediates used in this process | RICHTER GEDEON NYRT. (HU) | 2012-05-15 | — | — | US | disclosed |
| US-8178665-B2 | Process for the production of ezetimibe and intermediates used in this process | RICHTER GEDEON NYRT. (HU) | 2012-05-15 | — | — | US | disclosed |
| CN-101346349-B | Process for the preparation of ezetimibe and intermediates used in the process | RICHTER GEDEON NYRT | 2011-04-20 | — | — | CN | disclosed |
| EP-1963260-B1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT (HU) | 2010-11-03 | — | — | EP | disclosed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | disclosed |
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | RICHTER GEDEON NYRT. (HU) | 2009-08-27 | — | — | US | disclosed |
| CN-101346349-A | Process for the preparation of ezetimibe and intermediates used in the process | RICHTER GEDEON NYRT (HU) | 2009-01-14 | — | — | CN | disclosed |
| EP-1611120-A4 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007072088-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCES | RICHTER GEDEON NYRT. (HU) | 2007-06-28 | — | — | WO | disclosed |
| EP-1611120-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | Cortical Pty Ltd (AU) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004089927-A1 | NOVEL METHODS FOR THE TREATMENT OF INFLAMMATORY DISEASES | CORTICAL PTY LTD (AU) | 2004-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090216009-A1 | PROCESS FOR THE PRODUCTION OF EZETIMIBE AND INTERMEDIATES USED IN THIS PROCESS | APOB, HMGCR, PCSK9 | HSD11B1 47/4885FFAR4 411/4885LMNA 2067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.